

# **Tuberculosis in pediatric population**



**By**

**Assoc. Prof. Keswadee Lapphra**

**Department of Pediatrics**

**Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand**




*For Myanmar Medical Association TB Forum 3 February 2018, Yangon*

# Scope

- **Management of childhood TB**
  - **Diagnosis of TB**
  - **Treatment TB in children**
- **LTBI**
- **The challenges**

# TUBERCULOSIS

## WHO Global Tuberculosis Report 2017



An estimated 10.4 million people fell ill with TB in 2016

An estimated 490 000 new cases of MDR-TB in 2016


9.7% of people with MDR-TB are estimated to have XDR-TB



**47% drop in TB death rate**  
since 1990, with nearly all  
improvement since 2000



**43 million lives saved**  
between 2000 and 2014 through  
effective diagnosis and treatment



**TB ranks alongside HIV**  
**as a leading cause of death**  
with 1.5 million TB deaths in 2014\*

10% of TB cases were children, 6.3% of new cases were <15 yo

# Criteria for Diagnosis of Childhood Tuberculosis

- **Clinical compatibility: Prolonged fever, weight loss, anorexia, anemia, prolonged cough > 2 weeks**
- **Hx of TB contact or Tuberculin skin test (TST) / IGRAs positive**
- **Chest X-rays compatible with TB**


# **Diagnosis of TB could be difficult due to non-specific presentations**





# Case 1: A 2 year-old boy with fever, cough, and rhinorrhea for 2 weeks


- 6 d PTA he developed seizure without meningeal sign. Dx febrile convulsion
- 4 d PTA he had high fever, lethargy and developed generalized seizure. PE : T 39° C, E<sub>1</sub>V<sub>T</sub>M<sub>5</sub>, spasticity, + neck stiffness
- LP: P > 60/47 cmH<sub>2</sub>O  
WBC 560 cells/mm<sup>3</sup> (L100%), protein 1,780 mg/dl, sugar 25/125 mg/dl



# Case 1: Investigations

- PPD skin test: negative
- Gastric wash AFB :  
negative for 3 days
- CSF PCR for TB: positive
- C/S for TB: no growth
- Anti-HIV: Negative

*Contact investigation for TB  
was performed*



**CXR of his  
mother**

# **Management 1:**

## **Diagnosis of TB requires high index of suspicion**

- **Always think of TB if insidious onset and not improved by other treatments**
- **Persistent coughing >2 weeks**
- **Unresolving pneumonia**
- **Unexplained prolonged fever**
- **Unexplained weight loss despite nutritional Rx**
- **Unexplained lethargy**
- **For infants: hepatosplenomegaly, sepsis with insidious onset**
- **CNS involvement with hydrocephalus**



# At Siriraj Hospital 2008-2011

- TB was diagnosed in 230 children
- The median age was 6.5 years (4 d -17.5 years)
- HIV infection 9.6%
- Clinical presentation
  - Prolonged cough >14 days 32.2%
  - Prolonged fever >14 days 28.7%
  - Weight loss 15.2%
  - Asymptomatic 29.6% (with contact Hx 63.5%)

# Approaches to Diagnosis of Childhood TB

- **Careful history taking** esp. history of TB contact in the last 24 months. High index of suspicion for extrapulmonary TB
- **Careful physical examination** including growth assessment
- **Test for Immunological evidence of TB infection**
  - TST  $\geq 10$  mm. ( $\geq 5$  mm if HIV-infected, severe malnourished)
  - IGRAs (interferon-g release assays) in immunocompetent > 5 yo if available
- **An HIV test** (HIV-positive result should probably be treated as a proxy for TB)
- **Bacteriological confirmation** whenever possible


# TST and IGRAs in children < 5 years

## Siriraj Hospital

Test results	Total N=60	TB exposed N=43	TB disease N=17
<b>TST</b>			
Positive (%)	15 (25.0)	10 (23.3)	5 (29.4)
≥ 10 mm. (%)	15 (25.0)	10 (23.3)	5 (29.4)
≥ 15 mm. (%)	5 (8.3)	3 (7.0)	2 (11.8)
<b>QFT-GIT</b>			
Positive (%)	8 (13.3)	5 (11.6)	3 (17.6)
Indeterminate (%)	0 (0)	0 (0)	0 (0)
<b>T-SPOT.TB.</b>			
Positive (%)	12 (20.0)	8 (18.6)	4 (23.5)
Borderline (%)	2 (3.3)	1 (2.3)	1 (5.9)
Indeterminate (%)	2 (3.3)	1 (2.3)	1 (5.9)

# CXR is Recommended for screening

FIG. 3. WHO's recommended screening strategy for TB prevalence surveys (21)



CXR: chest X-ray.

THE  
**END TB**  
STRATEGY



- 23% and 70% of bacteriologically confirmed TB had chronic cough.
- Half will be missed by symptom screening alone
- To increase sensitivity, intentional overreading of CXRs should be encouraged
- Any abnormal CXR should get bacteriological examination, regardless of symptoms
- Immunocompromised person often shows atypical manifestations in a CXR

# Management 2:

## Rapid drug susceptibility testing

- **Rapid drug susceptibility testing (DST) of isoniazid and rifampicin or of rifampicin alone is recommended over conventional testing or no testing at the time of diagnosis of TB, subject to available resources.**  
***(conditional recommendation, very low quality evidence).***




# Conventional Test

- **Direct Susceptibility Test:**


- Directly from clinical sample: Smear “positive”
- M7H10 agar
- Isoniazid and Rifampicin
- Turnaround Time: 4 wks

- **Indirect Susceptibility Test:**


- From pure culture
- Turnaround Time: 4 weeks
- M7H10 agar or LJ or MGIT



# GeneXpert MTB/RIF




# Distribution of MDR-TB determining mutations





# Line Probe Assay



**Figure 4. Line-probe assays for detection of drug resistance. (A) Principle of reverse hybridization. (B) INNO-LiPA® assay.** The INNO-LiPA test contains ten oligonucleotide probes (one specific for the *Mycobacterium tuberculosis* complex, five overlapping wild-type S probes, and four R probes for detecting specific mutations) that are immobilized on nitrocellulose strips. LIPA is performed by extracting DNA and amplifying the rifampicin resistance-determining region of the *rpoB* gene using PCR. The PCR products are then hybridized with the immobilized probes, and results are determined by colorimetric development. Image adapted from Innogenetics NV (Gent, Belgium) © 2006 Innogenetics Group.

# Management 3: Treatment in Children is not easy

- **No pediatric formulation in most anti-TB drugs**
- **Need DOT/adult supervision**
- **PK data recently available suggested that children have a lower exposure of anti-TB drugs compare to adults**



# WHO Recommendation of Treatment of TB in Children 2010

- Change dose recommended to avoid treatment failure while no evidence of increased hepatotoxicity (reported varied 1-80% incidence)
  - INH : 10 MKD (10-15 MKD, max 300 mg/d)
  - RIF : 15 MKD (10-20 MKD, max 600 mg/d)
  - PZA : 35 MKD (30-40 MKD)
  - ETB : 20 MKD (15-25 MKD) >>> *unchanged*
- *Avoid streptomycin as the first line*
- Use IRZE in intensive phase for all except in not extensive lesion in area with low HIV and low INH-resistance that can use 3 drug IRZ

*(Strong recommendation, moderate quality evidence)*

# Regimens for Rx tuberculosis

<b>Tuberculosis</b>	<b>Regimens</b>
<b>Pulmonary TB</b>	<b>2 IRZE/4 IR</b>
<b>TB osteomyelitis, TB meningitis, Disseminated TB</b>	<b>2 IRZE/10 IR</b>
<b>MDR-TB</b>	<b>At least 4 active drugs Fluoroquinolone+ Aminoglycoside 2<sup>nd</sup> line: Ethio/Cycloserine/PAS Bedaquiline/Delamanid</b>

**Prednisolone 4 - 8 wk in TB meningitis, paradoxical reaction (Miliary TB 30% had CNS involvement)**

# WHO Recommendation 2010

**Not recommend twice weekly, but trice-weekly continuation phase may be considered in HIV-uninfected children with well-established DOT (*Weak recommendation, very low quality evidence*)**


Author	Dose/wk	N	Cure rate Intermittent VS Daily
Kumar 1990	twice	76	93% VS 100%
Te Water 2000	twice	213	89% VS 97%
Al-Dossary 2002	Twice from wk3	185	37%
Ramachancran 1998	Twice wk 1-8 IRZ then twice IRZ (Daily only IR)	141	48% VS 60%

*Menon et al. (meta analysis): twice/wk less likely to cure (PP or 0.27 95% CI 0.15-0.51  
ITT or 0.66, 95% CI 0.23-1.84)*

# Case : An 18 month-old with miliary TB

- 18 month old girl with prolonged fever and chronic cough. CXR found miliary TB. IRZS was started.
- 4 weeks later, she had weakness of left leg with long track sign, hyper-reflexia.

CSF wbc = 350 (L90%), sugar was 30 mg%, protein was 250 mg%



***The CNS symptoms may be presented after Rx initiation.***

# Treat Military TB as CNS TB

- **For military TB, look for CNS involvement. LP should be done**

**- 75% (12/16) of patients with military TB had CNS involvement identified by MRI. Of these, only half had symptoms...** *Sasaki Y. Kekkaku*

*2000;75:423-7.*

**- 20-30% of patients with CNS TB had military TB...** *Yamaris A. Pediatrics 1998;102: E49., van den Bos F.*

*Trop Med Int Health 2004;9:309-13.*



# Prevalence, Characteristics, Management, and Outcome of Pulmonary Tuberculosis in HIV-Infected Children in the TREAT Asia Pediatric HIV Observational Database (TApHOD)

- **457/ 2678 HIV-infected children developed PTB over a 13-year period; prevalence of 17.1% (range 5.7-33.0% per country).**
- **There were 21 deaths (4.3%).**
- **One third of episodes (n=175/484) occurred after ART initiation at a median of 14.1 months**
- **After Rx, 81.9% had good outcomes**

**Management 4 :  
Drug resistance in  
childhood TB is  
rising, shadowing  
what seen in adults**

# Case: A 2 month-old male infant with hydrocephalus


- He was well looking and sent to Siriraj Hosp. for evaluated the cause of hydrocephalus.
- CSF : WBC 12 cells/mm<sup>3</sup>  
(L76%, Mono 23%)  
protein 82 mg/dl, sugar 29 mg/dl  
C/S no growth, AFB –ve,  
**PCR TB +ve**
- Gastric aspirate: AFB –ve x 3 days  
**PCR TB +ve**
- Contact Inx in family: CXR  
6 people negative



[illegible]

# Prevalence of and risk factors for resistance to second-line drugs in people with MDR TB in 8 countries: a prospective cohort study

*Previous treatment with 2<sup>nd</sup> line drugs associated with resistance to the drugs*






# **Management 5: Control of Childhood TB**

**The best control of childhood TB is to treat active adult case early and perform contact investigation in children**

**Don't forget to check out  
household members**

**TB of Spine: Contact with father who had TB 3 years earlier  
but never been told to bring the child in for check -up**





**1/3 of the  
World  
population is  
believed  
to have LTBI**

# Latent Tuberculosis

- **The condition that infection is established, but disease has not occurred**
- **Mostly diagnosed by reactive TST or IGRA in asymptomatic individuals**
- **It is the quiet period which may progress to TB or resolution of the infection**
- **It is the window of opportunity to prevent TB development**


# Risk factors for the development of active TB among persons infected with *M. tuberculosis*

Risk factor	Estimated risk for TB relative to persons with no known risk factor
High risk (testing and treatment for LTBI recommended for all ages)	
AIDS (not on anti-HIV therapy)	110–170
HIV (not on anti-HIV therapy)	50–110
Transplantation (related to immunosuppressive therapy)	20–74
Silicosis	30
Chronic renal failure requiring hemodialysis	10–25
Carcinoma of head and neck	16
Recent TB infection (<2 yrs)	15
Abnormal chest X ray—with upper lobe fibronodular disease typical of healed TB infection	6–19
TNF- $\alpha$ inhibitors	2–9
Moderate risk (testing and treatment for LTBI recommended if age < 65 yrs)	
Treatment with glucocorticoids	5
Diabetes mellitus (all types)	2–4
Young age when infected (0–4 yrs)	2–5
Slightly increased risk (testing and treatment for LTBI recommended if age < 50 yrs)	
Underweight (<90% ideal body weight; for most persons, this is a BMI of 20)	2–3
Cigarette smoker (1 pack/day)	2–3
Abnormal chest X ray—granuloma	2
Low risk (testing and treatment for LTBI recommended if age < 35 yrs)	
Infected person, no known risk factor, normal chest X ray ("low-risk reactor")	1
Very low risk (treatment of LTBI not usually recommended)	
Person with positive two-step ("boosting"), no other known risk factor, and normal chest X ray	0.5

\*Modified from the work of Lobue and Menzies (140) and the CDC.

Haley CA. *ASMscience.org/MicrobiolSpectrum* 2017.  
*Respirology* 2010;15:603–622. *Semin Respir Crit Care Med* 2013; 34:67–86.

# Contact investigation and Management





# Regimens Used for LTBI treatment

Regimen	Efficacy	Adherence	Incidence of drug-induced hepatitis
Daily H 6 mo	69%	50%	1-5%
Daily H 9-12 mo	90-93%	< 50%	1-5%
Daily RH 3-4 mo	~ 6 mo H	Slightly better (by 6%) than 9-12 mo H	1-5%
Daily RZ 2 mo	~ 9-12 mo H	Slightly better (by 6%) than 9-12 mo H	3-5%
Daily R 3-4 mo	65%	Much better (by 22%) than 9-12 mo H	<1%
Twice-weekly RH 3 mo	~ 6 mo H	95%	2.4%
Weekly RH 3 mo	~ 9 mo H	82-96%	0.4-1.5%



# 30 Years Study Confirmed INH prophylaxis works in Children and Adolescents

***Need to put INH prophylaxis in TB-exposed/LTBI in children. Not too early, but not too late***

**Rate TB(/1,000) in  
INH Rx vs no Rx**


---

**At 20 yr. report                      4.2 vs 10.1**

**At 30 yr. report (for <3 yo.)    0.5 vs 7.5**

# Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection

A Modified Intention-to-Treat Population




No. at Risk

Isoniazid only	3745	3644	3599	3555	3513	3484	3454	3405	3394	3310
Combination therapy	3986	3866	3827	3799	3783	3752	3726	3675	3661	3577

**Rifapentine + INH for 3 mo was as effective as 9 mo of INH alone in preventing TB and had a higher treatment-completion rate**

# Treatment for preventing tuberculosis in children and adolescents: RCT of a 3-month, 12-dose regimen of a combination of rifapentine and INH vs INH alone



**12 dose  
combo had  
higher  
completion  
rate  
(88% VS 81%)  
with  
similar AE  
compared to  
INH alone**

No. of TB Cases and Event Rates by Treatment Arm (MITT Population)


Treatment Arm	No.	TB Cases <sup>a</sup>	TB per 100 Patient-Years	Cumulative TB Rate, %	Difference in Cumulative TB Rates	One-sided 97.5% CI <sup>b</sup>
Isoniazid only	434	3	0.27	0.74	-0.74	0.32
Combination drug therapy	471	0	0.00	0.00		

**Q wk by DOT**


Villarino ME. *JAMA Pediatr* 2015;169(3):247-55.

# Newborn contact maternal TB


- Mother 21 yr. G<sub>2</sub>P<sub>1</sub>A<sub>0</sub> GA 38 wk ANC x11 times, serology negative all
- Hx of chronic cough 8 months before delivery, no fever, No TB in her family
- CXR
- Sputum : AFB 2+
  - Direct PCR : + TB complex
  - C/S: *M.tuberculosis* complex
  - Direct PCR : no mutation in *rpoB* gene, *katG* gene, *inhA* gene



# Infant born to mother with tuberculosis who received appropriate Rx > 3 months




# Newborn contact maternal TB



- **CBC: Hb 15.8 g/dl, Hct 46.3%, WBC 10,000/ul (N 51.3%, L 35.3%, Mo 7.3%, Eo 5.9%), Plt 143,000/ul**
- **CSF: WBC 1 , RBC 3, protein 114, sugar 59/blood sugar 111**
- **CSF : AFB neg., PCR-TB neg, C/S no growth for bacteria**
- **Gastric wash x 3 days: AFB neg, PCR-TB neg, c/s neg**

# Newborn contact maternal TB

- Rx congenital pneumonia
  - Ampicilline + gentamicin x 7 days




**CXR F/U after Rx pneumonia**

**Contact TB: Isoniazid prophylaxis 9 months**



# Infant born to mother with pulmonary TB



**Not considered a contra-indication to breastfeeding  
TB drugs don't harm the neonate**

**Give vitamin B6 0.2-0.5 mg/day in infant who receiving INH**

# The Challenges



# Challenges




**Meds in 1 day**  
**Cycloserine (+B6),**  
**PAS, Ethionamide,**  
**Levoflox**  
**+ amikacin IV OD**



# Directly observe therapy (DOT)



# Enhanced DOT may be helpful



N = Number of studies

Modified DOT = DOT while hospitalization (or a portion)

Enhanced DOT = DOT with enablers (to assist pts. to complete Rx)  
+ incentive



# Treating Adolescents is HARD



**Case : A 15 year-old girl who does not want to take the meds**

*CXR at 9 M of treatment with poor compliance*



# Conclusion: Management of Childhood TB

- **Diagnosis: need better tests, invest in development of new tools & research**
- **Treatment: need more children friendly formulations, DOT, anti TB drugs for MDR/XDR**
- **Control: need active case finding and Rx in adults, prophylaxis to prevent TB in children**

ကျေးဇူးတင်ပါတယ်



**THANK YOU**  
for your attention